FinanceCity
HealthcareNSE · BSE

Ipca Laboratories Ltd.

IPCALAB · ISIN INE571A01038

Share price

₹1,559 -1.06%

Market capitalisation

₹39552 CrClosed

Live from Yahoo Finance. Pulse animates during NSE market hours (9:15–15:30 IST, weekdays).

01 · Key metrics

Market cap

₹39552 Cr

Current price

₹1,559

-1.06% today

52W high

₹1,678

52W low

₹1,252

Stock P/E

34.71

P/B ratio

4.9

02 · Per share & returns

EPS (TTM)

₹44.91

Book value

₹318

ROE

13.22%

ROA

8.08%

Dividend yield

0.38%

Beta

0.06

03 · Financials (TTM)

By the numbers

Revenue

₹9646 Cr

+6.20% YoY

EBITDA

₹1979 Cr

Net profit

₹1141 Cr

+341.60% YoY

Profit margin

11.83%

Operating margin

15.77%

Total debt

₹809 Cr

Total cash

₹1198 Cr

Debt / equity

0.08x

Current ratio

2.76x

Payout ratio

4.45%

04 · Analyst view

Target price

₹1,720

Upside

+10.30%

Consensus

BUY

Analysts

18

05 · Shareholding pattern

Who owns IPCALAB?

  • Promoters

    44.72%

    Founders & promoter group

  • Institutions

    45.33%

    FII + DII

  • Public

    9.95%

    Retail & non-institutional

As of 31 Mar 2026 · Source: NSE corporate filings

06 · Registration & listing

On the record

Symbol
IPCALAB
Exchange
NSE · BSE
CIN
ISIN
INE571A01038
BSE code
524494
Sector
Healthcare
Industry
Healthcare
Face value
₹1
Listing date
07 Feb 1995
Employees
Headquarters
Mumbai, India

07 · About

What is Ipca Laboratories Ltd.?

Ipca Laboratories Limited, an integrated pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India, Europe, Africa, the Americas, Asia, the Commonwealth of Independent States, and Australasia. The company offers APIs in anti-hypertensive, anti-malarial, diuretic, DMARD, anti-hypertensive, and anthelmintic therapeutic areas. It also provides generic and branded formulations in various therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, diabetes, dermatology, diabetology, emollients/protectives, fever, gastroenterology, helminthics, hepatoprotectives, immunosuppressant, infectious diseases, malaria, neurology, neuropathic pain, and NSAIDs, as well as nutraceuticals, ophthalmology, oral anti diabetes drug, orthopedics, probiotics, psychiatry, respiratory, rheumatology, and urology. The company also exports its products worldwide. Ipca Laboratories Limited was incorporated in 1949 and is based in Mumbai, India.

08 · Common questions

Frequently asked

What is the CIN of Ipca Laboratories Ltd.?+

The Corporate Identity Number for Ipca Laboratories Ltd. is published in the MCA21 corporate master. FinanceCity backfills CIN values during weekly refreshes.

Who are the promoters of Ipca Laboratories Ltd.?+

Promoter holding in IPCALAB is approximately 44.72%, as disclosed in the latest published shareholding pattern.

What is the market capitalisation of Ipca Laboratories Ltd.?+

Ipca Laboratories Ltd. (IPCALAB) has a market capitalisation of approximately ₹39552 Cr, reflecting the most recent weekly refresh from the BSE scrip master.

09 · Adjacent

Other healthcare listings

Full sector →